A5027101830- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Glioma Diagnosis and Treatment
- Hormonal and reproductive studies
- Radiopharmaceutical Chemistry and Applications
- Brain Metastases and Treatment
- Meningioma and schwannoma management
- Cancer, Lipids, and Metabolism
- Vascular Malformations Diagnosis and Treatment
- Effects of Radiation Exposure
- Health Systems, Economic Evaluations, Quality of Life
- Medical Imaging Techniques and Applications
- Bladder and Urothelial Cancer Treatments
- Advances in Oncology and Radiotherapy
- Radiomics and Machine Learning in Medical Imaging
- Cancer Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Statistical Methods in Clinical Trials
- Radiation Dose and Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- Intracranial Aneurysms: Treatment and Complications
- Lung Cancer Research Studies
- Advanced Proteomics Techniques and Applications
- Management of metastatic bone disease
Ottawa Hospital
2016-2025
University of Ottawa
2015-2025
Ottawa Regional Cancer Foundation
2006-2024
ISS International (South Africa)
2021-2024
Queen's University
2013-2024
Population Services International
2023
Ottawa Hospital Research Institute
2015-2023
Population Services International
2023
University Hospitals Seidman Cancer Center
2021
McMaster University
2020
Purpose: Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean tissue. These physical changes can negatively affect health-related quality life. Resistance exercise help to counter some these side effects by reducing elevating mood, building muscle mass, fat. Methods: In two-site study, 155 who were scheduled receive androgen for at least 3 months after recruitment randomly assigned...
Radiotherapy for prostate cancer (PCa) may cause unfavorable changes in fatigue, quality of life (QOL), and physical fitness. We report results from the Prostate Cancer Exercise Versus Normal Treatment study examining effects 24 weeks resistance or aerobic training versus usual care on QOL, fitness, body composition, prostate-specific antigen, testosterone, hemoglobin, lipid levels men with PCa receiving radiotherapy.Between 2003 2006, we conducted a randomized controlled trial Ottawa,...
We evaluated whether the timing of fatal myocardial infarction (MI) was influenced by administration androgen suppression therapy (AST).The study cohort comprised 1,372 men who were enrolled onto three randomized trials between February 1995 and June 2001. In trials, randomly assigned to receive radiation with 0 versus 3 6, 8, or 6 months AST. Fine Gray's regression used determine clinical factors associated time MI, estimates MI calculated using a cumulative incidence method. When comparing...
Intermittent androgen deprivation for prostate-specific antigen (PSA) elevation after radiotherapy may improve quality of life and delay hormone resistance. We assessed overall survival with intermittent versus continuous in a noninferiority randomized trial.
Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT postoperative after radical prostatectomy is unclear.
Three small retrospective studies have suggested that patients undergoing continuous androgen deprivation (CAD) superior survival and time to progression if lower castrate levels of testosterone (< 0.7 nmol/L) are achieved. Evidence from prospective large has been lacking.The PR-7 study randomly assigned experiencing biochemical failure after radiation therapy or surgery plus CAD intermittent deprivation. The relationship between in the first year cause-specific (CSS) androgen-independent...
This phase II study was designed to determine the efficacy of mammalian target rapamycin (mTOR) inhibitor everolimus administered daily with conventional radiation therapy and chemotherapy in patients newly diagnosed glioblastoma.Patients were randomized concurrent adjuvant temozolomide or without (10 mg). The primary endpoint progression-free survival (PFS) secondary endpoints overall (OS) treatment-related toxicities.A total 171 deemed eligible for this study. Patients receive experienced...
Androgen deprivation with medical castration has been the mainstay treatment for metastatic prostate cancer. However, there are several drawbacks to prolonged androgen deprivation, including development of tolerance (loss dependence) and adverse effects on quality life. In mice tumor models dependence, followed by re-exposure androgens before progression preserved dependence. The possible value this strategy studied in human Several phases 2 3 clinical studies suggest that intermittent can...
Dose-escalated radiotherapy (RT) with androgen-deprivation therapy (ADT) is a standard definitive treatment of localized prostate cancer (LPCa). The optimal sequencing these therapies unclear. Our phase III trial compared neoadjuvant versus concurrent initiation ADT in combination dose-escalated RT (PRT).Patients newly diagnosed LPCa Gleason score ≤ 7, clinical stage T1b to T3a, and prostate-specific antigen < 30 ng/mL were randomly allocated for 6 months starting 4 before (neoadjuvant...